M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Long-Term Survival in Patients with Glioblastoma Multiforme
TL;DR: It is concluded that among patients with glioblastoma multiforme, long-term survival is most likely for those who have a long disease-free interval after the initial diagnosis and receive multimodal therapy, including aggressive tumor removal.
Journal ArticleDOI
Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
Timothy F. Cloughesy,Patrick Y. Wen,H. Ian Robins,Susan M. Chang,Morris D. Groves,Karen Fink,Larry Junck,David Schiff,Lauren E. Abrey,Mark R. Gilbert,Frank S. Lieberman,John G. Kuhn,Lisa M. DeAngelis,Minesh P. Mehta,Jeffrey J. Raizer,W. K. Alfred Yung,Kenneth Aldape,John Tim Wright,Kathleen R. Lamborn,Michael D. Prados +19 more
TL;DR: Tipifarnib (300 mg bid for 21 days every 4 weeks) shows modest evidence of activity in patients with recurrent GBM who are not receiving EIAEDs and is generally well tolerated in this population.
Journal Article
Serial Proton MR Spectroscopic Imaging of Recurrent Malignant Gliomas after Gamma Knife Radiosurgery
Edward E. Graves,Sarah J. Nelson,Daniel B. Vigneron,Lynn Verhey,Michael W. McDermott,David A. Larson,Susan M. Chang,Michael D. Prados,William P. Dillon +8 more
TL;DR: Evaluation of metabolic changes with proton MR spectroscopy and structural changes with MR imaging improved tissue discrimination and provided correlation with histologic findings.
Journal ArticleDOI
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D. Norden,Jeffrey J. Raizer,Lauren E. Abrey,Kathleen R. Lamborn,Andrew B. Lassman,Susan M. Chang,W. K. Alfred Yung,Mark R. Gilbert,Howard A. Fine,Minesh P. Mehta,Lisa M. DeAngelis,Timothy F. Cloughesy,H. Ian Robins,Kenneth Aldape,Janet Dancey,Michael D. Prados,Frank S. Lieberman,Patrick Y. Wen +17 more
TL;DR: Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma.
Journal ArticleDOI
Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome.
Nancy J. Fischbein,Michael D. Prados,William M. Wara,Carolyn Russo,Michael S. B. Edwards,A. J. Barkovich +5 more
TL;DR: It is suggested that the most important factor in determining prognosis based on MR characteristics is whether the tumor is diffuse or focal, and focal tumors have an excellent prognosis regardless of the site of tumor origin.